

China Respiration System Chemical Medicine Industry Competitive Landscape and Leading Enterprise Research Report, 2013-2017

目 录

CONTENTS

Chapter 1: Development Overview of China Respiratory System Chemical Medicine Industry

1.1 Concept of Respiratory System Chemical Medicine Industry

- 1.1.1 Definition of Respiratory System Chemical Medicine Industry
- 1.1.2 Scope Definition of Report on Respiratory System Chemical Medicine Industry
- 1.1.3 Analysis System for Report on Respiratory System Chemical Medicine Industry

1.2 Features of Respiratory System Chemical Medicine Industry

- 1.2.1 Development Features of Respiratory System Chemical Medicine Industry
- 1.2.2 Influencing Factors of Respiratory System Chemical Medicine Industry

1.3 Policy Environment for Respiratory System Chemical Medicine Industry

- 1.3.1 Introduction and Explanation of Policies Related to Respiratory System Chemical Medicine Industry
- 1.3.2 Introduction and Explanation of Plans Related to Respiratory System Chemical Medicine Industry

Chapter 2: Development of Respiratory System Chemical Medicine Industry

2.1 Development Overview of Chemical and Pharmaceutical Industry

- 2.1.1 Development Overview of International Chemical and Pharmaceutical Industry
- 2.1.2 Development Overview of International Chemical and Pharmaceutical Industry
 - (1) Operation of Industry
 - (2) Industry Scale
 - (3) Competitive Landscape
 - (4) Trend Outlook

2.2 Development Overview of Respiratory System Chemical Medicine Industry

- 2.2.1 Concept and Classification of Industry
- 2.2.2 Operation of Industry
- 2.2.3 Market Scale of Industry
- 2.2.4 Development Trend for Industry
 - (1) Demand Forecast for Respiratory Drugs Industry
 - (2) Development Trend for Respiratory Drugs Industry

Chapter 3: Analysis of Competition for Nasal Spray Market Segments

3.1 Development Overview of Nasal Spray

3.2 Competition for Major Nasal Sprays

3.3 Nasal Spray Manufacturing Enterprises Compete for Position

3.4 Competition for Major Nasal Sprays in Domestic

- 3.4.1 Azelastine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 3.4.2 Mometasone
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 3.4.3 Oxymetazoline
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets

- (4) Drug Market Demand Trend
- 3.4.4 Levocabastine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 3.4.5 Xylometazoline
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend

3.5 Competition Trend for Nasal Spray

Chapter 4: Analysis of Competition for Throat Preparation Market Segments

4.1 Development Overview of Throat Preparation

4.2 Competition for Major Throat Preparations

4.3 Throat Preparation Manufacturing Enterprises Compete for Position

4.4 Competition for Major Throat Preparations in Domestic

- 4.4.1 Dequalinium Chloride
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 4.4.2 Cydiodine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 4.4.3 Cetrimide/ Benzalkonium Chloride
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 4.4.4 Lidocaine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend

4.5 Competition Trend for Throat Preparation

Chapter 5: Analysis of Competition for Anti-asthmatic Drug Market Segments in Domestic

5.1 Development Overview of Anti-asthmatic Drug

5.2 Competition for Anti-asthmatic Drugs

5.3 Anti-asthmatic Drug Manufacturing Enterprises Compete for Position

5.4 Competition for Major Anti-asthmatic Drugs in Domestic

- 5.4.1 Budesonide
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 5.4.2 Salmeterol/Fluticasone
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 5.4.3 Doxofylline
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 5.4.4 Montelukast

- (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 5.4.5 Compound Methoxyphenamine Hydrochloride
- (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 5.4.6 Budesonide/Formoterol
- (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend

5.5 Competition Trend for Anti-asthmatic Drug

Chapter 6: Analysis of Competition for Cough and Cold Medicine Market Segments in Domestic

6.1 Development Overview of Cough and Cold Medicine

6.2 Competition for Cough and Cold Medicines

6.3 Cough and Cold Medicine Manufacturing Enterprises Compete for Position

6.4 Competition for Major Cough and Cold Medicines in Domestic

6.4.1 Ambroxol

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

6.4.2 Bromhexine

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

6.4.3 Acetylcysteine

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

6.4.4 Eucalyptol/ Limonene and Pinene

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

6.5 Competition Trend for Cough and Cold Medicine

Chapter 7: Analysis of Competition for Antihistamines Market Segments in Domestic

7.1 Development Overview of Antihistamines

7.2 Competition for Antihistamines

7.3 Antihistamines Manufacturing Enterprises Compete for Position

7.4 Competition for Major Antihistamines in Domestic

7.4.1 Loratadine

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

7.4.2 Cotirizine

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

7.4.3 Desloratadine

- (1) Basic Information

- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend
- 7.4.4 Mizolastine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 7.4.5 Levocetirizine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 7.4.6 Ebastine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend
- 7.4.7 Epinastine
 - (1) Basic Information
 - (2) Competition Position for Major Manufacturing Enterprises
 - (3) Competitive Landscape of Regional Drug Markets
 - (4) Drug Market Demand Trend

7.5 Competition Trend for Antihistamines

Chapter 8: Analysis of Competition for Other Domestic Respiratory System Medicines Market

8.1 Development Overview of Other Respiratory System Medicines

8.2 Competitive Landscape for Other Major Respiratory System Medicines

8.3 Competitive Position of Other Respiratory System Medicine Manufacturing Corporations

8.4 Competition for Parts of Other Respiratory System Medicines

8.4.1 Pulmonary Surfactant

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

8.4.2 Dermatophagoides Farinae

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

8.4.3 Calf Pulmonary Surfactant

- (1) Basic Information
- (2) Competition Position for Major Manufacturing Enterprises
- (3) Competitive Landscape of Regional Drug Markets
- (4) Drug Market Demand Trend

Chapter 9: Analysis of Leading Enterprises in Respiratory System Chemical Medicine Industry

9.1 Overall Situation of Respiratory System Chemical Medicine Manufacturing Enterprises

- 9.1.1 Comprehensive Overview of Respiratory System Chemical Medicine Manufacturing Enterprises
- 9.1.2 Sales Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises
- 9.1.3 Total Profit Ranking of Respiratory System Chemical Medicine Manufacturing Enterprises

9.2 Leading Brands in Respiratory System Chemical Medicine Manufacturing Enterprises and Their Investment Layout in China

9.2.1 Pfizer

- (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Pfizer Dalian Plant
- 1) Profile

- 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.2 Novartis AG
- (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Beijing Novartis Pharma Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.3 Merck
- (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Hangzhou Moshadong Pharmaceutical Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
 - (6) Operation Situation of Shanghai Schering-Plough Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.4 Sanofi
- (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.5 Roche Holding Ltd.
- (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Shanghai Roche Pharmaceutical Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability

- 6) Development Capability
- 9.2.6 Glaxo Smith Kline
 - (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Shanghai Glaxosmithkline Biological Products Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.7 AstraZeneca
 - (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Jiangsu AstraZeneca Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.8 Johnson & Johnson
 - (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Xian Janssen Pharmaceutical Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.9 Eli Lilly
 - (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Eli Lilly and Company
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability
 - 5) Debt-paying Ability
 - 6) Development Capability
- 9.2.10 Boehringer Ingelheim
 - (1) Development Profile
 - (2) Sales Network
 - (3) Product Structure
 - (4) Operation Situation
 - (5) Operation Situation of Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd.
 - 1) Profile
 - 2) Production and Marketing Capability
 - 3) Profitability
 - 4) Operation Capability

- 5) Debt-paying Ability
- 6) Development Capability

9.3 Case Study of Leading Enterprises of Domestic Respiratory System Chemical Medicine Industry

9.3.1 Shenzhen Daphne Pharmaceuticals Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

9.3.2 Changzhou Jinyuan Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

9.3.3 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

9.3.4 Beijing Wellso Pharmaceutical Co., Ltd.

- (1) Development Overview
- (2) Product and Market Positioning
- (3) Situation of Market Distribution
- (4) Profile of Major Respiration System Drugs
- (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
- (6) Operational Advantages and Disadvantages
- (7) Investment, M&A and Restructuring
- (8) Latest Development Trend

- 9.3.5 Heilongjiang Fuhe Huaxing Pharmaceutical Co., Ltd.
 - (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.6 Reyoung Pharmaceutical Co., Ltd.
 - (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.7 Southwest Pharmaceutical Co., Ltd.
 - (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.8 Beijing Jiuhe Pharmaceutical Co., Ltd.
 - (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.9 Jiangxi Kelun Pharmaceutical Co., Ltd.
 - (1) Development Overview
 - (2) Product and Market Positioning

- (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.10 Tianjin Pharmaceutical Research Institute Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.11 Beijing Laneva Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.12 ChongQing Carelife Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.13 Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation

- 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.14 Hunan Jiudian Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.15 Guizhou Yunfeng Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.16 Shenzhen Haibin Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.17 Biochemical Pharmaceutical Factory of Zhuhai S.E.Z
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability

- 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.18 Changzhou Siyao Pharmaceuticals Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.19 Chongqing Huapont Pharm. Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.20 Yangtze River Pharmaceutical Group
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.21 Hainan Poly Pharm Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages

- (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.22 Beijing Double-Crane Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend
- 9.3.23 Jiangsu Nhwa Pharmaceutical Co., Ltd.
- (1) Development Overview
 - (2) Product and Market Positioning
 - (3) Situation of Market Distribution
 - (4) Profile of Major Respiration System Drugs
 - (5) Overall Operation
 - 1) Production and Marketing Capability
 - 2) Profitability
 - 3) Operation Capability
 - 4) Debt-paying Ability
 - 5) Development Capability
 - (6) Operational Advantages and Disadvantages
 - (7) Investment, M&A and Restructuring
 - (8) Latest Development Trend

如需了解报告详细内容，请直接致电前瞻客服中心。

全国免费服务热线：400-068-7188 0755-82925195 82925295 83586158

或发电子邮件：service@qianzhan.com

或登录网站：<https://bg.qianzhan.com/>

我们会竭诚为您服务！